inWhite tw_white-black
MoreMenu
CloseWhite
inWhite tw_white-black

News

Asgard Therapeutics’ study published in Science showing proof-of-concept and strong anti-tumor responses via in vivo cell reprogramming with lead program AT-108

Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage

Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology

Asgard Therapeutics to present positive in vivo efficacy data with AT-108 as monotherapy at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting 

Asgard Therapeutics and its founders were featured as the example spin-off from Lund University 

Posted 7 September, 2022

Asgard Therapeutics, founded by CEO Cristiana Pires, Head of Research Fábio Fiúza Rosa, and Head of Innovation Filipe Pereira, exemplifies a successful spin-off from Lund University. They took their innovative research within cancer immunotherapy all the way from the academic setup to the creation of the company that raised EUR 6M for its development.